I-Mab, TRACON Pharmaceuticals begins human trial of CD73 antibody TJD5
Category: #health  By Pankaj Singh  Date: 2019-08-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

I-Mab, TRACON Pharmaceuticals begins human trial of CD73 antibody TJD5

The study will evaluate the tolerability and safety of TJD5 and determine recommended doses for future clinical studies.

I-Mab Biopharma (I-Mab), a clinical stage biopharmaceutical firm focused on the discovery and development of biologics in immuno-oncology, has announced that cancer drug maker TRACON Pharmaceuticals has dosed its first patient in a U.S. Phase 1 first-in-human clinical trial of CD73 antibody TJD5, a proprietary of I-Mab, in patients with advanced solid tumors.

According to reports, the company will dose TJD5 in the 1st Phase of its trials, both as a single agent and in combination with TECENTRIQ®, a PD-L1 antibody retailed by Roche. For the record, I-Mab and Roche entered into a research collaboration on April 2019, where Roche agreed to supply TECENTRIQ® to I-Mab for testing in combination with TJD5 in a clinical study.

Speaking on the announcement, Joan Shen, M.D., Ph.D., Head of R&D, I-Mab Biopharma, said that TJD5 is the third internally discovered drug developed by the company to enter clinical studies in the U.S. She said that the ‘Fast-to-PoC Global Approach’ plays an essential role for advancing the company’s proprietary drug candidates towards acceptance in the U.S, which further deepens their partnership with TRACON.

Shen added that the treatment resistance to PD-L1/ PD-1 inhibitors are one of the key challenges across cancer types and the company hopes the combination of TECENTRIQ® and TJD5 will offer a new treatment option to counter the unmet medical needs.

According to Charles Theuer, M.D., Ph.D., President and CEO, TRACON Pharmaceutical, signing this partnership contract with I-Mab is an essential milestone as both the parties have expanded their immune-oncology pipeline and validated TRACON’s product manufacturing capabilities designed to lower the time and cost of clinical development for its partners.

He said that their firm will continue to work with I-Mab to optimize the clinical development of TJD5, an antibody with best-in-class, global potential.

Source Credit: http://www.i-mabbiopharma.com/en/article-321.aspx

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Yumanity starts Phase 1 trial of YTX-7739 to treat Parkinson’s disease
Yumanity starts Phase 1 trial of YTX-7739 to treat Parkinson’s disease
By Pankaj Singh

Number of cases where people are affected with neurodegenerative diseases have been growing at a substantial pace. Alzheimer’s disease and Parkinson’s disease are the most common neurodegenerative diseases found across the world. Various ...

AngioDynamics buys Eximo Medical and its 355nm Laser Atherectomy tech
AngioDynamics buys Eximo Medical and its 355nm Laser Atherectomy tech
By Pankaj Singh

Owing to widescale tobacco use, the world is seeing an increased number of cancer and vascular diseases. India alone registers more than 10 million cases of peripheral artery disease on an annual basis. Technology and healthcare enterprises are incre...

Scholar Rock to showcase preclinical, phase 1 clinical data of SRK-015
Scholar Rock to showcase preclinical, phase 1 clinical data of SRK-015
By Pankaj Singh

SMA is a rare genetic disease that typically affects young children. Currently, there is no cure for spinal muscular atrophy (SMA), however, various pharmaceutical firms across the world are working to discover a novel, innovative treatment for the d...